Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Vanda Pharmaceuticals Reports Second Quarter 2011 Results

August 4, 2011 By Bio-Medicine.Org

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ — Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ:
VNDA
), a biopharmaceutical company focused on the development
and commercialization of products for central nervous system
disorders, today announced financial and operational results for
the second quarter and six months ended June 30, 2011.

“We are pleased with our progress towards our vision of building
a CNS specialty pharmaceutical company.  Fanapt® scripts
in the U.S. continued to grow, and we have made advances towards
the globalization of the franchise.  We are excited about the
prospects of our tasimelteon programs in both Non-24 and major
depression, which are currently underway,” said Mihael
Polymeropoulos, M.D., President and Chief Executive Officer.

Key Highlights:

Vanda recorded second quarter 2011 revenue of $7.4
million including royalties of $0.8 million. Second quarter sales
of Fanapt® as reported by Novartis included a $2.7 million
cumulative adjustment to gross to net sales reserves that resulted
in approximately $270 thousand less in royalties to Vanda in the
period
. Fanapt® prescriptions, as reported by
IMS, reached 30,000 in the second quarter of 2011.  This
represents a 17% increase over first quarter 2011 prescriptions.
 
On July 22, 2011, the European Medicines Agency (EMA)
notified Vanda that it had accepted for evaluation the Marketing
Authorization Application (MAA) for oral iloperidone tablets.

Vanda announced commercialization agreements for two Latin
American markets.  On July 11, 2011, Vanda entered into an
exclusive license agreement with Probiomed S.A. de C.V. (Probiomed)
for the commercialization of Fanapt® in Mexico.   On
August 1, 2011, Vanda entered into an exclusive license agreement
with Biotoscana Farma S.A. (Biotoscana

‘/>”/>

SOURCE

Related Articles Read More >

A rat holding its face with its paws
Ultrasound research with rats shows potential for depression therapy
Tivic Health CEO Jennifer Ernst
Sinus pain is just the beginning for Tivic Health’s CEO
A series of before-and-after brain scans showing improvement in long COVID patients after hyperbaric oxygen therapy
Long COVID study finds potential in hyperbaric oxygen therapy
microrobot-purdue-university
This microrobot device could remove brain hemorrhages caused by stroke

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech